AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
GSK Sees Positive Updates for Shingrix and Tebipenem HBr Treatments
ByAinvest
Tuesday, Oct 21, 2025 4:40 am ET1min read
GSK reports positive updates on Shingrix and tebipenem HBr. The European Medicines Agency has given a positive opinion for Shingrix in a prefilled syringe, simplifying the vaccine administration process. GSK and Spero Therapeutics also announced positive phase III data for tebipenem HBr, showing it is effective in treating complicated urinary tract infections. GSK plans to file for approval in the US in Q4. Shares in GSK were up 0.5% on the news.
GSK (GlaxoSmithKline) has announced positive developments for two of its key products. The European Medicines Agency (EMA) has given a positive opinion for Shingrix in a prefilled syringe, simplifying the vaccine administration process. Additionally, GSK and Spero Therapeutics have reported positive phase III data for tebipenem HBr, demonstrating its effectiveness in treating complicated urinary tract infections (UTIs).The prefilled syringe presentation of Shingrix (recombinant zoster vaccine [RZV]) has been approved by the FDA for the prevention of shingles (herpes zoster), eliminating the need for healthcare professionals to reconstitute separate vials prior to administration, according to .
The positive opinion from the EMA further supports GSK's commitment to enhancing adult immunization rates. The prefilled syringe presentation is currently undergoing regulatory review by the EMA, with filing acceptance received in January 2025. GSK has indicated it is exploring submission of this presentation to other markets as part of its commitment to increasing adult immunization rates, as noted by Patient Care Online.
In parallel, GSK and Spero Therapeutics have reported positive phase III data for tebipenem HBr, a novel antibiotic aimed at treating complicated UTIs. The data show that tebipenem HBr is effective in treating these infections, which can be challenging to treat with existing therapies. GSK plans to file for approval in the US in Q4 2025, according to .
Shares in GSK were up 0.5% on the news, reflecting investor confidence in the company's pipeline and the positive regulatory outlook for both Shingrix and tebipenem HBr.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet